Bronchopulmonary Dysplasia – Global Pipeline Review, H1 2019 –

May 14, 2019 Off By BusinessWire

DUBLIN–(BUSINESS WIRE)–The “Bronchopulmonary
Dysplasia – Pipeline Review, H1 2019”
drug pipelines has been
added to’s offering.

Bronchopulmonary Dysplasia – Pipeline Review, H1 2019
provides comprehensive information on the therapeutics under development
for Bronchopulmonary Dysplasia (Respiratory), complete with analysis by
stage of development, drug target, mechanism of action (MoA), route of
administration (RoA) and molecule type. The guide covers the descriptive
pharmacological action of the therapeutics, its complete research and
development history and latest news and press releases.

The Bronchopulmonary Dysplasia (Respiratory) pipeline guide also reviews
of key players involved in therapeutic development for Bronchopulmonary
Dysplasia and features dormant and discontinued projects. The guide
covers therapeutics under Development by
Companies/Universities/Institutes, the molecules developed by Companies
in Filing rejected/Withdrawn, Phase II, Phase I, IND/CTA Filed,
Preclinical and Discovery stages are 1, 3, 1, 1, 10 and 2 respectively.
Similarly, the Universities portfolio in Preclinical stages comprises 1
molecules, respectively.


  • The pipeline guide provides a snapshot of the global therapeutic
    landscape of Bronchopulmonary Dysplasia (Respiratory).
  • The pipeline guide reviews pipeline therapeutics for Bronchopulmonary
    Dysplasia (Respiratory) by companies and universities/research
    institutes based on information derived from company and
    industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of
    development ranging from pre-registration till discovery and
    undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline
    products which comprise, product description, descriptive licensing
    and collaboration details, R&D brief, MoA & other developmental
  • The pipeline guide reviews key companies involved in Bronchopulmonary
    Dysplasia (Respiratory) therapeutics and enlists all their major and
    minor projects.
  • The pipeline guide evaluates Bronchopulmonary Dysplasia (Respiratory)
    therapeutics based on mechanism of action (MoA), drug target, route of
    administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued
    pipeline projects.
  • The pipeline guide reviews latest news related to pipeline
    therapeutics for Bronchopulmonary Dysplasia (Respiratory).

Reasons to Buy

  • Procure strategically important competitor information, analysis, and
    insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio
    and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under
    development for Bronchopulmonary Dysplasia (Respiratory).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of
    leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players
    and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding
    Bronchopulmonary Dysplasia (Respiratory) pipeline depth and focus of
    Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by
    identifying prospective partners with the most attractive projects to
    enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects
    and understand from the know-how what drove them from pipeline.

Companies Mentioned

  • Chiesi Farmaceutici SpA
  • Ethypharm SA
  • Insmed Inc
  • MediPost Co Ltd
  • Meridigen Biotech Co Ltd
  • Radikal Therapeutics Inc
  • Syntrix Biosystems Inc
  • Takeda Pharmaceutical Co Ltd
  • The Cell-Factory BVBA
  • Therabron Therapeutics Inc
  • United Therapeutics Corp

For more information about this drug pipelines report visit

Laura Wood, Senior Press Manager
[email protected]
E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call
For GMT Office Hours Call +353-1-416-8900
Topics: Respiratory